Cerus Corp
CERS
Company Profile
Business description
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Contact
1220 Concord Avenue
Suite 600
ConcordCA94520
USAT: +1 925 288-6000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2024
Employees
280
Cerus Corp News & Analysis
funds
No room on the ARK?
If performance turns for the worst, money that has been quick to come may be quicker yet to go, writes Morningstar's Ben Johnson.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,683.50 | 50.40 | 0.58% |
| CAC 40 | 7,255.01 | 41.69 | 0.58% |
| DAX 40 | 19,322.59 | 176.42 | 0.92% |
| Dow JONES (US) | 44,296.51 | 426.16 | 0.97% |
| FTSE 100 | 8,262.08 | 112.81 | 1.38% |
| HKSE | 19,229.97 | 371.14 | -1.89% |
| NASDAQ | 19,003.65 | 31.23 | 0.16% |
| Nikkei 225 | 38,283.85 | 257.68 | 0.68% |
| NZX 50 Index | 13,082.67 | 40.77 | 0.31% |
| S&P 500 | 5,969.34 | 20.63 | 0.35% |
| S&P/ASX 200 | 8,443.00 | 49.20 | 0.59% |
| SSE Composite Index | 3,267.19 | 103.21 | -3.06% |